SPX4,026.12-1.14 -0.03%
DIA343.52+1.57 0.46%
IXIC11,226.36-58.96 -0.52%

HC Wainwright & Co. Maintains Buy Rating for Satsuma Pharmaceuticals: Here's What You Need To Know

Benzinga · 11/15/2022 12:01

HC Wainwright & Co. has decided to maintain its Buy rating of Satsuma Pharmaceuticals (NASDAQ:STSA) and lower its price target from $18.00 to $3.00.

Shares of Satsuma Pharmaceuticals are trading down 7.24% over the last 24 hours, at $0.63 per share.

A move to $3.00 would account for a 375.96% increase from the current share price.

About Satsuma Pharmaceuticals

Satsuma Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.